Skip to main content
CTVA logo

Corteva, Inc. (CTVA) Stock: Price, Forecast & Analyst Target

Corteva, Inc. (CTVA) — MoonshotScore 51/100 (Fair band), calculated Nov 18, 2026. Price $8.12 (-2.87%), as of the Nov 19, 2026 trading session; market cap $5.42B. Expected results Feb 2, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$8.12 −$0.24 (-2.87%) Market Cap $5.42B

Corteva, Inc. · CTVA · NYSE · Basic Materials · Agricultural Inputs

Research dated 2026-09-12: Corteva sells seed genetics, traits, crop-protection products and farm decision tools, making farmer product selection and crop-protection demand more important than the broad agricultural-input label suggests. Its case rests on whether rising operating profit can endure when revenue softens and seasonal cash conversion weakens.

Price as of Nov 19, 2026

Key Statistics

51 of 100

MoonshotScore v2 · Corteva (CTVA)

Fair
Business Quality Solid (61)
Financial Safety Okay (56)
Valuation Cheap (87)
Growth Durability Flat (57)
Momentum Quiet (43)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Cheap, but the fundamentals are only middling. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and reported profit not backed by cash flow. Business Quality: Solid; Financial Safety: Okay; Valuation: Cheap; Growth Durability: Flat; Momentum: Quiet.

  • EPS beat 6 of the last 8 reports
  • expected results Feb 2, 2027
  • Altman Z 0.94 · Piotroski F 5

Helping: an attractive price

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for CTVA (57 recorded, newest six shown)
RecordedScoreBand
83Exceptional
75Strong
54Fair
54Fair
51Fair
51Fair

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$8.12
Change on the day-2.87%
52-week range$8.12–$14.62
Market capitalisation$5.42B—
Price / earnings (trailing)7.29
Shares traded on the day19.97M
Beta (volatility vs the S&P 500)0.59

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $8.12, high $13, latest $8.12. $13 $8.12 high $13 Oct 17, 2025 Nov 19, 2026 · $8.12 $9.21Oct 17, 2025$9.22Oct 31, 2025$9.90Nov 14, 2025$10Nov 28, 2025$9.92Dec 12, 2025$10Dec 26, 2025$10Jan 9, 2026$11Jan 23, 2026$11Feb 6, 2026$11Feb 20, 2026$12Mar 6, 2026$12Mar 20, 2026$13Apr 2, 2026$12Apr 17, 2026$12May 1, 2026$12May 15, 2026$12May 29, 2026$11Jun 12, 2026$12Jun 26, 2026$13Jul 10, 2026$13Jul 24, 2026$12Aug 7, 2026$12Aug 21, 2026$13Sep 4, 2026$12Sep 18, 2026$12Oct 2, 2026$13Oct 16, 2026$12Oct 30, 2026$9.43Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Corteva (CTVA): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Neutral
Valuation Strong
Growth Durability Neutral
Momentum Neutral

Legends Council

4 lenses, 4 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 19, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Undervalued
Profit Margin Weak
Debt/Equity Neutral
Gross Margin Moderate

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 18, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Corteva (CTVA), and what does it report?

Short answer · as of

Seed revenue comes from germplasm and traits designed around yield, weather, disease, insects and herbicide resistance; Crop Protection supplies herbicides, insecticides, fungicides, nitrogen stabilizers and seed-applied technologies.

Digital tools support product selection rather than forming the core reported business.

Seed contributes the larger revenue base, while Crop Protection supplies a substantial complementary stream. Quarterly revenue, profit and cash flow swing markedly across the agricultural selling cycle, so an isolated period can give a distorted view of underlying economics.

2 · Latest results

What do the latest results show for Corteva (CTVA)?

The latest reported period paired a modest revenue decline with lower gross profit and net income, yet operating profit increased. That improvement therefore appeared below gross profit rather than through sales acceleration; research and selling expenses shown in the statement did not decline.

Reported earnings exceeded the market estimate while revenue fell short, reversing the prior period’s combination of revenue and earnings outperformance. Across the latest annual record, revenue and net income improved, but the recent quarterly pattern remains uneven rather than a clean acceleration.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
Sep 30, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Jun 2025$6.46B$1.31B—
Sep 2025$2.62B-$320M-$0.47 (diluted)
Q4 FY2025$3.91B-$552M-$0.82 (diluted)
Q1 FY2026$4.91B$720M$1.07 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Corteva (CTVA)?

Short answer

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Cash and investments do not cover total debt, although reported liquidity ratios indicate adequate near-term coverage and leverage remains modest relative to equity. The balance sheet therefore has flexibility, but it is not a net-cash cushion.

Cash generation is sharply seasonal, with heavy outflows near the opening of the annual cycle and large inflows near year-end. The latest midyear period remained cash-flow negative after the comparable period had turned positive, even though the cash balance finished only modestly below its level at the start of the reported window.

A thin free-cash-flow yield, modest returns on assets and equity, and a demanding earnings multiple leave the valuation dependent on continued profit improvement. Weak farmer demand would pressure Seed and Crop Protection through the same agricultural purchasing cycle.

4 · What to check next?

What should you watch next at Corteva (CTVA)?

Short answer · as of

The next earnings report is expected on Feb 2, 2027.

Corteva’s next scheduled report arrives in a seasonally weaker part of its reporting cycle, with consensus anticipating a loss and revenue near the recent trough range. The useful checks are whether revenue holds above the prior seasonal low, whether operating-profit resilience survives softer volume, and whether cash begins its customary recovery.

Longer-range estimates imply gradual revenue and earnings expansion rather than an abrupt change in scale. Progress would look more convincing if earnings gains remain accompanied by revenue growth and a renewed year-end cash inflow.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Corteva compare with its peers?

Short answer

Corteva's score ranks 12th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Corteva is not simply a commodity chemical supplier. Its larger Seed operation monetizes germplasm and traits, while Crop Protection sells chemistry and seed-applied technologies; digital selection tools connect those offerings to farm decisions.

That portfolio gives Corteva exposure to intellectual property in seed as well as recurring crop-protection demand, supported by rising research spending. A pure seed or pesticide business lacks this same operating mix, while Corteva must fund innovation across the combined portfolio.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
AngloGold Ashanti Plc (AU) Named competitor$77.01 Nov 19, 2026$39.0B99 5-pillar Nov 18, 2026
CF Industries Holdings, Inc. (CF) Same industry, near in market value$113.70 Nov 18, 2026$16.6B98 5-pillar Nov 18, 2026
Wheaton Precious Metals Corp. (WPM) Named competitor$120.27 Nov 18, 2026$54.6B91 5-pillar Nov 18, 2026
Nucor Corporation (NUE) Named competitor$247.43 Nov 19, 2026$55.7B85 5-pillar Nov 18, 2026
Intrepid Potash, Inc. (IPI) Same industry, near in market value$29.50 Nov 19, 2026$394M77 5-pillar Nov 18, 2026
CVR Partners, LP (UAN) Same industry, near in market value$95.93 Nov 19, 2026$1.10B70 5-pillar Nov 18, 2026
Nutrien Ltd. (NTR) Same industry, near in market value$65.41 Nov 19, 2026$31.0B70 5-pillar Nov 18, 2026
ICL Group Ltd (ICL) Same industry, near in market value$4.14 Nov 19, 2026$5.69B62 5-pillar Nov 18, 2026
Vale S.A. (VALE) Named competitor$9.83 Nov 19, 2026$41.8B60 5-pillar Nov 18, 2026
The Scotts Miracle-Gro Company (SMG) Same industry, near in market value$61.38 Nov 19, 2026$3.57B58 5-pillar Nov 18, 2026
Air Products and Chemicals, Inc (APD) Named competitor$303.83 Nov 19, 2026$67.7B53 5-pillar Nov 18, 2026
Corteva (CTVA) — this page$8.12$5.42B51
Hyperliquid Strategies, Inc. (PURR) Same industry, near in market value$7.95 Nov 18, 2026$2.21B42 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Basic Materials stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$11.00 – $101.00
Consensus target
$30.45
Median target
$17.00

Consensus record · Captured .

Measured against a quoted price of $8.12 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Nov 16, 2026

Transactions
17
Identified insiders
8
Purchases
3
Sales
0
Other transactions
14

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held CTVA in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Bridgewater AssociatesFounded by Ray DalioQ3 20260%$0Sold out (was $20.58M)

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Corteva (CTVA)?

Read these with our analysis →

CTVA Basic Materials Stock FAQ

The last 2 questions are answered from this page's own dated data, not from the research.

What does Corteva sell beyond crop-protection chemicals?

Corteva develops seed germplasm and traits for yield, resistance and nutritional characteristics, alongside digital tools that help farmers select products. Seed contributes more revenue than Crop Protection.

Why can Corteva report profit while operating cash flow is negative?

Accounting profit and cash timing diverge sharply across Corteva’s agricultural cycle. Recent history shows heavy cash outflows near the cycle’s opening and substantial inflows near year-end, even while reported earnings remain positive in some outflow periods.

Is Corteva’s Seed business larger than Crop Protection?

Seed supplies the larger share of segment revenue, with Crop Protection providing the complementary chemistry and seed-applied portfolio. That mix makes Corteva more than a pesticide producer.

Can Corteva sustain operating leverage through its seasonal low?

The latest period showed higher operating profit despite softer revenue and gross profit, but cash conversion weakened. Confirmation would require that profit resilience persist through the expected seasonal trough and that cash generation recover near year-end.

What is the CTVA stock price today?

The last price recorded for Corteva, Inc. (CTVA), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the CTVA price target?

The analyst consensus price target for Corteva, Inc. (CTVA), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 24 figures on this page — 1 from SEC filings and earnings calls, 18 from Financial Modeling Prep (FMP), 4 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Legal name; Business description; Revenue by segment; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions)
  • 1. What is Corteva (CTVA), and what does it report?: Business description; Revenue by segment; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Annual revenue and net result (USD millions)
  • 2. What do the latest results show for Corteva (CTVA)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Reported versus estimated, last 8 quarters
  • 3. What are the financial strengths and risks for Corteva (CTVA)?: Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Cash against market value; Trailing twelve-month ratio set; Operating cash flow by quarter (USD millions); Distress and quality screens; Revenue by segment; Business description
  • 4. What should you watch next at Corteva (CTVA)?: Next earnings report; Analyst revenue and earnings estimates (average); Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Reported versus estimated, last 8 quarters
  • 5. How does Corteva compare with its peers?: Business description; Sector / industry (provider taxonomy); Revenue by segment; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands)
  • FAQ: What does Corteva sell beyond crop-protection chemicals?: Business description; Revenue by segment
  • FAQ: Why can Corteva report profit while operating cash flow is negative?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions)
  • FAQ: Is Corteva’s Seed business larger than Crop Protection?: Revenue by segment; Business description
  • FAQ: Can Corteva sustain operating leverage through its seasonal low?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Next earnings report; Cash and short-term investments over time (USD millions)
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold CTVA

Funds in our ETF coverage that list CTVA among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
FTAG ETF9.44%
First Trust Indxx Global Natural Resources Income ETF (FTRI)9.28%
T. Rowe Price Natural Resources ETF (TURF)5.38%